OVID THERAPEUTICS INC (OVID) Stock Price & Overview
NASDAQ:OVID • US6904691010
Current stock price
The current stock price of OVID is 2.94 USD. Today OVID is up by 5.38%. In the past month the price increased by 41.62%. In the past year, price increased by 866.74%.
OVID Key Statistics
- Market Cap
- 444.028M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.31
- Dividend Yield
- N/A
OVID Stock Performance
OVID Stock Chart
OVID Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to OVID. When comparing the yearly performance of all stocks, OVID is one of the better performing stocks in the market, outperforming 99.59% of all stocks.
OVID Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OVID. No worries on liquidiy or solvency for OVID as it has an excellent financial health rating, but there are worries on the profitability.
OVID Earnings
On March 18, 2026 OVID reported an EPS of 0.06 and a revenue of 718.00K. The company beat EPS expectations (149.43% surprise) and beat revenue expectations (5180.73% surprise).
OVID Forecast & Estimates
17 analysts have analysed OVID and the average price target is 4.81 USD. This implies a price increase of 63.45% is expected in the next year compared to the current price of 2.94.
For the next year, analysts expect an EPS growth of -70.18% and a revenue growth -97.57% for OVID
OVID Groups
Sector & Classification
OVID Financial Highlights
Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 18.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.54% | ||
| ROE | -13.33% | ||
| Debt/Equity | 0 |
OVID Ownership
OVID Latest News, Press Relases and Analysis
OVID Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.06 | 365.196B | ||
| AMGN | AMGEN INC | 15.34 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.9 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.14 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.22 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.2 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.84 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.6 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OVID
Company Profile
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Company Info
IPO: 2017-05-05
OVID THERAPEUTICS INC
441 Ninth Avenue, 14Th Floor
New York City NEW YORK 10036 US
CEO: Jeremy M. Levin
Employees: 23
Phone: 18009279800
OVID THERAPEUTICS INC / OVID FAQ
Can you describe the business of OVID THERAPEUTICS INC?
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
What is the stock price of OVID THERAPEUTICS INC today?
The current stock price of OVID is 2.94 USD. The price increased by 5.38% in the last trading session.
Does OVID THERAPEUTICS INC pay dividends?
OVID does not pay a dividend.
What is the ChartMill technical and fundamental rating of OVID stock?
OVID has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is OVID THERAPEUTICS INC worth?
OVID THERAPEUTICS INC (OVID) has a market capitalization of 444.03M USD. This makes OVID a Small Cap stock.
Can you provide the ownership details for OVID stock?
You can find the ownership structure of OVID THERAPEUTICS INC (OVID) on the Ownership tab.